A Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Protective Efficacy and Immunogenic Persistence of the Bivalent Human Papillomavirus Vaccine (Pichia Pastoris) Administered to Healthy Females Aged 18-30 During the 311-HPV-1003 Study
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant 9 valent Shanghai Zerun Biotechnology (Primary)
- Indications Human papillomavirus infections
- Focus Therapeutic Use
- Sponsors Shanghai Zerun Biotechnology Co
- 21 Jan 2025 New trial record